GlassScriptPhysician profile
John Webster Jameson
NPI 1902802853
$10,572.22
in general payments reported to CMS, 2019-2025
50 companies · $1,371 in 2025
The $1,371 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,706 · 2020: $1,646 · 2021: $1,976 · 2022: $928 · 2023: $1,294 · 2024: $1,651 · 2025: $1,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,315.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,225.30 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,205.44 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $804.24 | 2019-2025 | |
| Amgen INC. | $778.89 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $650.80 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $642.03 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $540.98 | 2020-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Glaxosmithkline, LLC. | $403.20 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Janssen Pharmaceuticals, INC | $368.45 | 2019-2021 | |
| Pfizer INC. | $358.43 | 2019-2025 | |
| Esperion Therapeutics, INC. | $354.11 | 2020-2024 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $257.67 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $244.34 | 2022-2024 | Quviviq |
| Amarin Pharma, INC. | $238.98 | 2019-2021 | |
| Daiichi Sankyo INC. | $231.47 | 2021-2025 | Injectafer |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Jameson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.